Bioethics Program, Department of Social and Preventive Medicine, School of Public Health, University of Montreal, Montréal, Québec, Canada.
Centre de Recherche en Santé Publique, Montreal, Québec, Canada.
BMC Med Ethics. 2020 Apr 3;21(1):25. doi: 10.1186/s12910-020-00466-6.
Chemotherapy and/or radiotherapy treatments may cause premature ovarian failure and irreversible loss of fertility. In the context of childhood cancers, it is now acknowledged that possible negative effects of therapies on future reproductive autonomy are a major concern. While a few options are open to post-pubertal patients, the only immediate option currently open to pre-pubertal girls is cryopreservation of ovarian tissue and subsequent transplantation. The aim of the study was to address a current gap in knowledge regarding the offer of fertility preservation by Ovarian Tissue Cryopreservation (OTC) for prepubescent girls with cancer, and to explore current practices and attitudes of Canadian, French and Moroccan pediatric heme oncologists. The comparative perspective is relevant since legal frameworks surrounding fertility preservation and funding offered by the healthcare system vary greatly.
An online survey was sent to the 45 pediatric oncology centers in Canada, France and Morocco.
A total of 39 centers responded (86.6%). OTC is offered by almost all pediatric heme oncologists in France (98%), very few in Canada (5%), and none in Morocco (0%). For pediatric hematologists/oncologists who do not propose fertility preservation in Canada, the reasons are: the technique is still experimental (54%), it is not available locally (26%) and cost of the technique for the family (14%). 97% of Canadian and 100% of Moroccan pediatric hematologists/oncologists think OTC should be funded by the healthcare system as it is in France and in the province of Quebec in Canada.
The results of this study show tremendous diversity in the provision of OTC across countries, whereby its offer is correlated with legislation and funding. We argue that the current reality, in which this technology is often not offered to families, raises ethical issues related to justice and equity of access, as well as informed consent and future reproductive autonomy.
化疗和/或放疗可能导致卵巢早衰和生育能力不可逆转的丧失。在儿童癌症的背景下,现在人们认识到治疗对未来生殖自主权的潜在负面影响是一个主要关注点。虽然青春期后患者有几种选择,但目前青春期前女孩唯一的即时选择是冷冻卵巢组织并随后进行移植。本研究旨在解决目前在向患有癌症的青春期前女孩提供卵巢组织冷冻保存(OTC)以保留生育能力方面存在的知识空白,并探讨加拿大、法国和摩洛哥儿科血液肿瘤学家的当前实践和态度。进行比较视角是相关的,因为围绕生育保护的法律框架和医疗保健系统提供的资金差异很大。
向加拿大、法国和摩洛哥的 45 个儿科肿瘤中心发送了在线调查。
共有 39 个中心(86.6%)做出了回应。法国几乎所有儿科血液肿瘤学家都提供 OTC(98%),加拿大很少(5%),摩洛哥则没有(0%)。对于不建议在加拿大进行生育保护的儿科血液科医生/肿瘤学家,原因是:该技术仍处于实验阶段(54%)、本地无法获得(26%)以及家庭的技术费用(14%)。97%的加拿大和 100%的摩洛哥儿科血液科医生/肿瘤学家认为 OTC 应该由医疗保健系统资助,就像在法国和加拿大魁北克省一样。
这项研究的结果表明,各国在提供 OTC 方面存在巨大差异,其提供与立法和资金有关。我们认为,目前这种技术通常不向家庭提供的情况引发了与获得公平性和公正性、知情同意和未来生殖自主权相关的伦理问题。